Naomi T Jessurun (Naomi Jessurun, N T Jessurun)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 29

Top Topics

Top Venues

Expert opinion on drug safety

British journal of clinical pharmacology

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Janneke M Quik, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman, Bartholomeus J F van den Bemt, Naomi T Jessurun
The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept. Expert opinion on drug safety (2024)
Marjolein Drent, Petal A Wijnen, Naomi T Jessurun, Ankie M Harmsze, Otto Bekers, Aalt Bast
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug safety (2024)
Marjolein Drent, Petal A Wijnen, Naomi T Jessurun, Ankie M Harmsze, Otto Bekers, Aalt Bast
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug safety 47 (4) (2024)
Marjolein Drent, Petal A Wijnen, Naomi T Jessurun, Ankie M Harmsze, Otto Bekers, Aalt Bast
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug safety 47 (4) (2024)
Benthe H König, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Bartholomeus J F van den Bemt, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. Expert opinion on drug safety (2024)
A Louters, M Van Oosterhout, L Burgemeister, Naomi T Jessurun, Jette A van Lint
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis. Rheumatology (Oxford, England) (2024)
Marjolein Drent, Petal A Wijnen, Naomi T Jessurun, Ankie M Harmsze, Otto Bekers, Aalt Bast
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug safety 47 (4) (2024)
Marjolein Drent, Petal A Wijnen, Naomi T Jessurun, Ankie M Harmsze, Otto Bekers, Aalt Bast
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug safety 47 (4) (2024)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Kimberly Velthuis, Fenna Poppelaars, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Kimberly Velthuis, Fenna Poppelaars, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Claudio Tana, Marjolein Drent, Hilario Nunes, Vasilis Kouranos, Francesco Cinetto, Naomi T Jessurun, Paolo Spagnolo
Comorbidities of sarcoidosis. Annals of medicine 54 (1) (2022)
Isa P A C Geeven, Naomi T Jessurun, Arthur T M Wasylewicz, Marjolein Drent, Phyllis I Spuls, Frank Hoentjen, Eugene P van Puijenbroek, Harald E Vonkeman, Koen P Grootens, Martijn Bastiaan Adriaan van Doorn, Bart J F van Den Bemt, Charlotte L Bekker
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. Expert opinion on drug safety 21 (5) (2022)
Henrike J Westerink, Leanne J Kosse, Naomi T Jessurun, Astrid van Tubergen, Harald E Vonkeman, Michael T Nurmohamed, Bart J F van den Bemt, Marieke de Vries
Patients' and health-care professionals' perspectives on adverse drug reaction burden attributed to the use of biological DMARDs: a qualitative study. Expert opinion on drug safety (2022)
Lieke H Roest, Leanne J Kosse, Jette A van Lint, Helen R Gosselt, Joep H G Scholl, Eugene P van Puijenbroek, Harald E Vonkeman, Sander W Tas, Michael T Nurmohamed, Bart J F van den Bemt, Naomi T Jessurun
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study. Expert opinion on drug safety (2022)
Merel de Boer, Helen R Gosselt, Jurriaan Jansen, Martijn Bastiaan Adriaan van Doorn, Frank Hoentjen, Michael T Nurmohamed, Phyllis I Spuls, Sander W Tas, Harald E Vonkeman, Naomi T Jessurun
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs). Expert opinion on drug safety (2022)
Jette A van Lint, Naomi T Jessurun, Renske C F Hebing, Frank Hoentjen, Sander W Tas, Harald E Vonkeman, Martijn B A van Doorn, Annemieke Sobels, Phyllis I Spuls, Eugene P van Puijenbroek, Michael T Nurmohamed, Bartholomeus J F van den Bemt
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug safety 43 (9) (2021)
Leanne J Kosse, Gerda Weits, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Phyllis I Spuls, Geert R A M D'Haens, Michael T Nurmohamed, Eugene P van Puijenbroek, Bart Jf Van Den Bemt, Naomi T Jessurun
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert opinion on drug safety 20 (12) (2021)
Jette A van Lint, Tom Bakker, Peter M Ten Klooster, Eugene P van Puijenbroek, Harald E Vonkeman, Naomi T Jessurun
Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert opinion on drug safety (2021)
Jette A van Lint, Florence P A M van Hunsel, Sander W Tas, Harald E Vonkeman, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Renske C F Hebing, Michael T Nurmohamed, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Annals of the rheumatic diseases 81 (4) (2021)
Arthur T M Wasylewicz, Britt W M van de Burgt, Aniek Weterings, Naomi T Jessurun, Erik H M Korsten, Antoine C G Egberts, Arthur R A Bouwman, Catharina H M Kerskes, Rene J E Grouls, Carolien van der Linden
Identifying adverse drug reactions from free-text electronic hospital health record notes. British journal of clinical pharmacology (2021)
Naomi T Jessurun, Hieronymus J Derijks, Rob J van Marum, Amy Jongkind, Eline L Giraud, Eugène P van Puijenbroek, Koen P Grootens
Body weight gain in clozapine-treated patients: Is norclozapine the culprit? British journal of clinical pharmacology (2021)
Eline L Giraud, Naomi T Jessurun, Florence P A M van Hunsel, Eugene P van Puijenbroek, Astrid van Tubergen, Peter M Ten Klooster, Harald E Vonkeman
Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert opinion on drug safety 19 (12) (2020)
Naomi T Jessurun, Annemieke Vermeulen Windsant, Oenone Mikes, Eugène P van Puijenbroek, Rob J van Marum, Koen Grootens, Hieronymus J Derijks
Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels-A prospective pharmacokinetic study. British journal of clinical pharmacology 87 (3) (2020)
Naomi T Jessurun, Petal A Wijnen, Aalt Bast, Eugène P van Puijenbroek, Otto Bekers, Marjolein Drent
Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers. International journal of molecular sciences 21 (8) (2020)